ArticlePediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2026
A circulating odd-chain fatty acid biomarker signature discriminates pediatric allergic rhinitis with asthma from related allergic airway phenotypes.
Article in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A circulating odd-chain fatty acid biomarker signature discriminates pediatric allergic rhinitis with asthma from related allergic airway phenotypes.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundReliable biomarkers for discriminating allergic rhinitis with asthma (ARA) from related allergic airway phenotypes remain lacking in pediatric populations. We aimed to identify and validate circulating metabolic biomarkers of ARA.
methodsSerum samples from 380 participants, including healthy controls (HC), allergic rhinitis (AR), asthma (AS), and ARA, underwent untargeted carboxylomics profiling using SPCSDCarboxyl. Candidate biomarkers were evaluated in mouse models and validated in an independent cohort (n = 125) using targeted carboxylomics. Biomarker performance was assessed using multivariate and machine-learning approaches.
resultsARA was associated with altered circulating odd-chain fatty acids (OCFAs), with valeric, heptanoic, nonanoic, undecanoic, and isovaleric acids showing consistent increased across cohorts. Heptanoic, nonanoic, and undecanoic acids demonstrated excellent discrimination of ARA from HC, with areas under curve (AUC) of 0.96, 0.98, and 0.94, respectively. However, these three OCFAs were broadly elevated across all allergic airway phenotypes and lacked ARA specificity. Least absolute shrinkage and selection operator (LASSO) regression identified valeric and undecanoic acids as complementary discriminatory features for ARA versus AR and AS. Among valeric acid showed the most phenotype-discriminatory performance, with an AUC of 0.72 for ARA versus AR and 0.64 for ARA versus AS. OCFA levels correlated significantly with inflammatory indices and pulmonary function, and comparable alterations were confirmed in mouse models.
conclusionsThese findings identify a pediatric ARA-specific OCFA signature of a distinct immunometabolic endotype involving propionyl-CoA metabolism and fatty acid oxidation. Valeric acid uniquely discriminated ARA from isolated AR, supporting its potential as a serum reference marker; combination with undecanoic acid or clinical parameters may further improve diagnostic performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.